Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C
Authors:
- Stefano VitiSVStefano Viti
- Audino PoddaAPAudino Podda
- Melecia Antonio VelmonteMVMelecia Antonio Velmonte
- Luciano NencioniLNLuciano Nencioni
- Rino RappuoliRRRino Rappuoli
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- INCREASE IN ADMISSIONS FOR NEISSERIA MENINGITIDIS INFECTION IN AUSTRALIAThe Lancet, 1989
- Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.Journal of Experimental Medicine, 1987
- Spectrophotometric method for the determination of cyanide and its application to biological fluidsThe Analyst, 1984
- Physicochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methodsVaccine, 1983
- Disuccinimidyl esters as bifunctional crosslinking reagents for proteinsFEBS Letters, 1979
- Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the futureImmunochemistry, 1978
- Clinical Efficacy of Meningococcus Group A Capsular Polysaccharide Vaccine in Children Three Months to Five Years of AgeNew England Journal of Medicine, 1977
- Structures of the Capsular Polysaccharides of Neisseria meningitidis as Determined by 13C-Nuclear Magnetic Resonance SpectroscopyThe Journal of Infectious Diseases, 1977
- An immunological study of the diphtheria toxin moleculeImmunochemistry, 1972
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970